February 3, 2023
You are here:  Home  >  Columns  >  Current Article

Dubroff: 5 reasons to pay attention to Amgen’s Otezla deal


Henry Dubroff
Henry Dubroff Merger Monday arrived on the Central Coast with a flourish on Aug. 26 when Amgen announced a $13.4 billion cash deal to buy the psoriasis drug Otezla from rival Celgene. In succeeding days, Amgen’s shares have continued to rise as analysts applauded a move that will give the Thousand Oaks-based pharma giant an…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.